Company profile

XOMA Royalty Corporation

Pipeline18 assets

Vabysmofaricimab-svoa / VABYSMO / VEGF/Ang-2 / Bispecific antibody / Ophthalmology
Neovascular age-related macular degeneration (nAMD) and Diabetic macular edema (DME)Approvedapproved
Ojemdatovorafenib / OJEMDA / Oncology
Oncology (undisclosed approved indication)Approvedapproved
Miplyffaarimoclomol / MIPLYFFA / Rare Diseases / Neurology
Niemann-Pick disease type C (NPC)ApprovedapprovedUS
Xaciatoclindamycin phosphate vaginal gel 2% / XACIATO / Small molecule / Gynecology / Infectious Disease
Bacterial VaginosisApprovedapproved
Ixinitycoagulation factor IX (recombinant) / IXINITY / Factor IX / Recombinant protein / Hematology
Hemophilia BApprovedapproved
Dsuviasufentanil sublingual tablet / DSUVIA / Opioid receptor / Small molecule / Pain Management
PainApprovedapproved
Dare to Playsildenafil cream / DARE to PLAY / PDE5 / Small molecule / Gynecology / Sexual Health
Female Sexual Arousal DisorderApprovedapproved
ersodetugRZ358 / INSR / Antibody / Metabolic Disorders
Hypoglycemia due to congenital hyperinsulinism (cHI)Phase 3ongoingHypoglycemia due to tumor hyperinsulinismPhase 3ongoing
RZ402RZ402 / Ophthalmology
Diabetic macular edema (DME)Phase 2ongoing
D-FiFCX-007 / Gene Therapy / Dermatology / Rare Diseases
Dystrophic epidermolysis bullosa (DEB)Phase 3ongoing
seralutinibGB002 / PDGFR, CSF1R, and c-KIT / Inhaled tyrosine kinase inhibitor / Respiratory / Cardiovascular
Pulmonary arterial hypertension (PAH)Phase 3ongoingPulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Phase 2ongoing
cetrelimabJNJ-63723283 / PD-1 / Antibody / Oncology / Infectious Disease
Muscle-invasive bladder cancer (MIBC)Phase 2ongoingChronic Hepatitis B Virus InfectionPhase 2ongoing
volixibatLUM-002 / Ileal bile acid transporter (IBAT) / Small molecule / Gastroenterology
Primary sclerosing cholangitis (PSC)Phase 2bongoingPrimary biliary cholangitis (PBC)Phase 2ongoing
osavampatorNeurology / Psychiatry
Major depressive disorderPhase 3ongoing
OHB-607OHB-607 / Recombinant human IGF-I/IGFBP-3 / Recombinant protein / Respiratory / Neonatology
Prevention of bronchopulmonary dysplasia in extremely premature infantsPhase 2ongoing
REC-4881REC-4881 / Allosteric MEK1/2 / Small molecule / Oncology
Familial adenomatous polyposisPhase 2ongoing
NIS793NIS793 / Antibody / Oncology
Solid tumorsPhase 3ongoing
QTORIN rapamycinQTORIN / mTOR / Small molecule / Dermatology / Rare Diseases
Cutaneous venous malformationsPhase 3ongoingClinically significant angiokeratomasPhase 2ongoing

Latest news3 items

Jul 14, 2026

XOMA Royalty Announces Closing of Its Acquisition by Ligand

EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty....

Jun 12, 2026

XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date

EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“ XOMA ” or the “ Company ”) today announced that its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s (i) 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq:...

Apr 27, 2026

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately...